Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$143.31 USD
-0.40 (-0.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $143.37 +0.06 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 241 - 260 ( 406 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Monsanto Alliance Brings in Additional Non-Dilutive Capital
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Monsanto Alliance Brings in Additional Non-Dilutive Capital
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M